Niagen Bioscience Engages Evotec for IND-Enabling Studies on NB4168 Ataxia Telangiectasia Candidate
- Niagen Bioscience selected Evotec to conduct pharmacokinetic, pharmacodynamic, and bioanalytical validation studies for NB4168, an oral small-molecule candidate for rare pediatric Ataxia Telangiectasia.
- Work will be performed at Evotec's Verona, Italy campus via its INDiGO integrated preclinical-to-clinical platform, generating data to support FDA IND submission.
- NB4168 has secured FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations; nonclinical studies show substantially higher blood exposure versus NR chloride.
Operational Impact
Evotec's INDiGO platform at Verona expands its integrated preclinical-to-IND service footprint for rare-disease sponsors, demonstrating demand for consolidated early-phase development capacity in Europe.
Source: PharmaSource RSS